AndhraNews.net
Home » Business News » 2011 » June » June 13, 2011

Biosimilar and Biomarker Approvals to Cut Costs - Research Report on Micromet, Inc. and CEL-SCI Corporation


June 13, 2011 - MACAU

Today, www.EquityMarketsInc.com announced its research report highlighting Micromet, Inc. (NASDAQ: MITI) and CEL-SCI Corporation (NYSE Amex: CVM). Full content and research is available at www.EquityMarketsInc.com/research.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Equity Markets has reviewed Micromet, Inc. because it is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. The Company's product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. As of December 31, 2009, five of its antibodies are in clinical trials, while the remainder of its product pipeline is in preclinical development. The full research report on Micromet, Inc. (NASDAQ: MITI) is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is Covering Cel-Sci Corporation as it is Engaged in the Business of Multikine Cancer Therapy; New Cold Fill Manufacturing Service to the Pharmaceutical Industry, and Ligand Epitope Antigen Presentation System (Leaps) Technology, With Two Products, Hemagglutinin Type 1 and Neuraminidase Type 1 (H1N1) swine flu Treatment for H1N1 Hospitalized Patients and Cel-2000, a Rheumatoid Arthritis Treatment Vaccine. the Full Research Report on Cel-Sci Corporation (NYSE Amex: CVM) is Available Here: Www.Equitymarketsinc.Com/Researchfile4891.Php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact:

Samuel Littman
Email Contact
www.EquityMarketsInc.com

MarketWire

Comment on this story

Share